Corindus Vascular Robotics Inc(NYSEMKT:CVRS) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 15, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $538.000K. Analysts estimated a revenue of $770.000K. The revenues were -30.13% below the estimates. Earnings per share were $-0.08. The reported EPS was below estimates by -14.29%. Analysts had estimated an EPS of $-0.07.
Corindus Vascular Robotics Inc (CVRS) made into the market gainers list on Fridays trading session with the shares advancing 2.92% or 0.04 points. Due to strong positive momentum, the stock ended at $1.41, which is also near the day’s high of $1.5088. The stock began the session at $1.36 and the volume stood at 16,62,072 shares. The 52-week high of the shares is $1.8 and the 52 week low is $0.4017. The company has a current market capitalization of $168 M and it has 11,90,25,221 shares in outstanding.
Corindus Vascular Robotics Inc. designs manufactures and sells precision vascular robotic-assisted systems for use in interventional vascular procedures (the CorPath System). The Company’s product the CorPath 200 System is a vascular robotic system which is engaged in stent placement in percutaneous coronary intervention (PCI) procedures. The CorPath System enables the robotic-assisted control of coronary guidewires and balloon/stent devices from the safety of a radiation-protected ergonomic interventional cockpit. It installed 24 CorPath Systems in hospitals in the United States and two CorPath Systems in hospitals outside of the United States. The CorPath System consists of two components: a bedside unit and an interventional cockpit. The CorPath System allows physicians to measure anatomy with sub-millimeter accuracy and manipulate the interventional device in one millimeter increments and with 30-degree rotational movements.